These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 36840914)

  • 21. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
    Shao T; Ren Y; Zhao M; Tang W
    Front Public Health; 2022; 10():912921. PubMed ID: 36045725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China.
    Wei J; Xu K; Lin Y; Liu Q; Zhou C; Zhang P; Ma R; Zhang M; Zhang L; Li X
    Int J Clin Pharm; 2024 Oct; 46(5):1189-1199. PubMed ID: 38814514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
    Liang X; Chen X; Li H; Liu X; Li Y
    Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.
    Lang W; Ai Q; He Y; Pan Y; Jiang Q; Ouyang M; Sun T
    Int J Clin Pharm; 2024 Dec; 46(6):1536-1545. PubMed ID: 39276261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US.
    Luo X; Cai T; Wu J; Li X; Wang X; Ma H
    Front Pharmacol; 2024; 15():1393559. PubMed ID: 39206260
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China.
    Zheng Z; Song X; Qiu G; Xu S; Cai H
    Curr Med Res Opin; 2023 Mar; 39(3):433-440. PubMed ID: 36757780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
    Tong YH; Ding HY; Xin WX; Zhong LK; Xu GQ; Zhang B; Yang GN; Fang L
    Tumori; 2022 Feb; 108(1):33-39. PubMed ID: 33511911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
    Shi Y; Wan X; Tan C; Li J; Peng L
    Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
    Cheng Y; Han L; Wu L; Chen J; Sun H; Wen G; Ji Y; Dvorkin M; Shi J; Pan Z; Shi J; Wang X; Bai Y; Melkadze T; Pan Y; Min X; Viguro M; Li X; Zhao Y; Yang J; Makharadze T; Arkania E; Kang W; Wang Q; Zhu J;
    JAMA; 2022 Sep; 328(12):1223-1232. PubMed ID: 36166026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
    Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
    PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China.
    Zhou D; Dong X; Zhou Z; Liu Q
    Risk Manag Healthc Policy; 2023; 16():2521-2529. PubMed ID: 38024490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
    Lin S; Luo S; Gu D; Li M; Rao X; Wang C; Huang P; Xu X; Weng X
    Oncologist; 2021 Nov; 26(11):e2013-e2020. PubMed ID: 34431578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
    Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
    Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis.
    Zhu Y; Liu K; Yang Q; Zeng M; Peng L
    Front Public Health; 2023; 11():1028202. PubMed ID: 37006537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China.
    Long Y; Wang H; Xie X; Li J; Xu Y; Zhou Y
    BMJ Open; 2024 Apr; 14(4):e077090. PubMed ID: 38582540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China.
    Li W; Wan L
    Front Public Health; 2022; 10():1015702. PubMed ID: 36408023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer.
    Li Y; Hu M; Zhang Z; Chu M; Xu R; Liu L; Dong W; Yang M; Zhang R
    Cancer Med; 2024 Jan; 13(1):e6904. PubMed ID: 38186268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China.
    Ma Y; Zhou J; Ye Y; Wang X; Ma A; Li H
    Front Oncol; 2023; 13():1113346. PubMed ID: 37182176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
    Wang T; Li Y; Zheng X
    BMC Health Serv Res; 2023 Jun; 23(1):691. PubMed ID: 37365540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.
    Ding D; Hu H; Liao M; Shi Y; She L; Yao L; Zhu Y; Zeng S; Huang J
    Adv Ther; 2020 May; 37(5):2116-2126. PubMed ID: 32193809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.